Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.

Bibliographic Details
Title: Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.
Authors: Yamaguchi K; Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer, Tokyo, Japan., Minashi K; Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan., Sakai D; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan., Nishina T; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan., Omuro Y; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan., Tsuda M; Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan., Iwagami S; Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan., Kawakami H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan., Esaki T; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Sugimoto N; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan., Oshima T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan., Kato K; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Amagai K; Department of Gastroenterology, Ibaraki Prefectural Central Hospital, Kasama, Japan., Hosaka H; Department of Gastroenterology, Gunma Prefectural Cancer Center, Ota, Japan., Komine K; Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan., Yasui H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan., Negoro Y; Department of Gastroenterology, Kochi Health Sciences Center, Kochi, Japan., Ishido K; Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan., Tsushima T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto, Japan., Han S; Biostatistics and Research Decision Sciences, MSD K.K., Tokyo, Japan., Shiratori S; Oncology Science Unit, MSD K.K., Tokyo, Japan., Takami T; Oncology Science Unit, MSD K.K., Tokyo, Japan., Shitara K; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.; Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Source: Cancer science [Cancer Sci] 2022 Aug; Vol. 113 (8), pp. 2814-2827. Date of Electronic Publication: 2022 Jul 01.
Publication Type: Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE
Database: MEDLINE Complete
Full text is not displayed to guests.
Description
ISSN:1349-7006
DOI:10.1111/cas.15462